CARsgen’s Kailimei wins clearance for late-line CLDN18.2-positive, HER2-negative gastric cancer, marking a milestone for cell therapy beyond blood cancers

CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors

The world’s first CAR-T therapy for solid tumors has passed muster in China, with the country's National Medical Products Administration (NMPA) giving the green light to CARsgen…

CARsgen’s Kailimei wins clearance for late-line CLDN18.2-positive, HER2-negative gastric cancer, marking a milestone for cell therapy beyond blood cancers

SHANGHAI, June 24, 2026 /PRNewswire/ -- Jiahui International Cancer Center (JICC) welcomes the approval of Satri-cel (CT041, Kaileimei®), the world's first CAR-T cell therapy…